Results 151 to 160 of about 36,039 (270)

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

American Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt, Christopher S. Wichman, Alyssa Bouska, Moataz Ellithi, Michael Haddadin, Javeed Iqbal, James E. Talmadge, Lori J. Maness, Krishna Gundabolu   +8 more
wiley   +1 more source

Umbilical cord blood infusion enhances hematopoietic recovery and improves survival in elderly AML patients with chemotherapy-induced myelosuppression: a retrospective study. [PDF]

Front Oncol
Zhou Y, Ren Y, Zhang L, Hu W, Ma J, Wang X.   +5 more
europepmc   +1 more source

Drug Induced Myelosuppression and Alopecia Totalis in Ulcerative Colitis Patient: Unmasking the Enigma

Azathioprine and Sulfasalazine are common drugs used in various conditions including inflammatory bowel disease (IBD) to induce remission and control the disease.
Mira Almheiri, Anjan Madasu, Ehsan Malik, Mohamad Sabsabee   +3 more
core   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Machine learning-based prediction and external validation of treatment-related myelosuppression in patients with non-small cell lung cancer receiving PD-1 inhibitors plus platinum-doublet chemotherapy. [PDF]

J Thorac Dis
Hui J, Hu R, Yang Z, Ding J, Guan Y, Li X, Li L.   +6 more
europepmc   +1 more source

Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study

American Journal of Hematology, Volume 101, Issue 10, Page 2672-2676, October 2026.
Elisa Buzzatti, Irene Terrenato, Martina Tomassi, Federica Lessi, Sara Pezone, Cristina Papayannidis, Gianluca Martini, Fabio Forghieri, Luana Fianchi, Martina Quattrone, Nicola Fracchiolla, Claudio Fozza, Michela Abbenante, Anna Lina Piccioni, Davide Facchinelli, Claudia Maria Basilico, Caterina Buquicchio, Nicola Di Renzo, Monica Piedimonte, Maria Giovanna Cefalo, Daniele Armiento, Adriano Venditti, Alessandro Busca, Francesco Marchesi, Maria Ilaria Del Principe, Livio Pagano   +25 more
wiley   +1 more source

Agreement in Staging and Treatment Recommendations Among Clinicians, Text‐Only Clinicians, DeepSeek‐V3, and ChatGPT‐4o for Nasopharyngeal Carcinoma Patients

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Purpose With AI tools being increasingly utilized for medical inquiries, this study evaluated the agreement between clinicians, text‐only clinicians, DeepSeek‐V3, and ChatGPT‐4o in TNM staging and preferred treatment recommendations for newly diagnosed nasopharyngeal carcinoma (NPC) patients.
Shenglan Lin, Cai Zhang, Feifei Zhong, Xiyi Liao, Liuyun Gong, Dunhuang Wang   +5 more
wiley   +1 more source

Myelosuppressive Chemotherapy [PDF]

, 2020
openaire   +1 more source

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Application of Population-Based Meta-Heuristic Algorithms for Robust Initialization in Mechanistic Pharmacometric Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lee D, Lin CW.
europepmc   +1 more source